Summary of DarioHealth (DRIO) Q3 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: $5 million for Q3 2025, down from $5.4 million in Q2 2025 and $7.4 million in Q3 2024.

Gross Margin: GAAP gross margin at 60%, up from 55% in Q2 2025 and 52% in Q3 2024; non-GAAP gross margin consistently above 80% since early 2024.

Operating Expenses: Reduced by $3.4 million (21%) year-over-year in Q3; total reduction of $17.2 million (31%) for the first nine months of 2025.

Cash Position: $31.9 million in cash and equivalents as of September 30, 2025, bolstered by a $17.5 million private placement.

Client Base: Over 125 clients, with 45 new accounts signed in 2025, surpassing the goal of 40.

2Strategic Updates and Business Highlights

DarioHealth emphasizes its unique multi-condition digital health platform, integrating physical, mental, and behavioral care.

More than 50% of new clients opted for the multi-condition solution, indicating a market shift towards comprehensive care.

Partnerships with major health plans like UnitedHealthcare and Primera Blue Cross are expected to enhance market reach and client engagement.

The company is transitioning to a recurring revenue model, focusing on high-margin, predictable revenue streams.

DarioHealth is also expanding its pharma services, targeting specific therapeutic areas to drive engagement and ROI.

3Forward Guidance and Outlook

Targeting $12.4 million in new business for implementation in 2026, with significant contributions expected from the current pipeline.

Anticipates reaching cash flow breakeven by late 2026 to early 2027.

Plans to further reduce operating expenses by an additional 10% to 15% over the next 12-15 months.

4Bad News, Challenges, or Points of Concern

Revenue decline attributed to the nonrenewal of a significant contract with a national health plan and the transition from milestone-based to recurring revenue in the pharma segment.

Sequential declines in B2B2C revenue, raising concerns about underlying business stability despite a strong client retention rate of 90%.

Competitive pressures and market dynamics may impact the uptake of multi-condition offerings, with only 50% of new clients choosing this option compared to 80% in the previous quarter.

5Notable Q&A Insights

The rollout with UnitedHealthcare is expected to be significant but specific revenue contributions were not disclosed.

The company is optimistic about the pacing of new business implementation, with most new accounts launching in Q1 2026.

Management acknowledged the impact of the previous nonrenewal on current revenue metrics but expressed confidence in the stability and growth potential of their core employer and health plan business.

Strategic partnerships and a refined go-to-market approach are seen as key drivers for future growth, with a focus on aligning product offerings with client needs and market demands. Overall, DarioHealth is navigating a transitional phase with a focus on enhancing its recurring revenue model, expanding its client base, and leveraging strategic partnerships, despite facing challenges related to revenue fluctuations and competitive pressures.